Published in Transl Lung Cancer Res on December 01, 2014
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget (2015) 0.98
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res (2016) 0.80
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget (2016) 0.79
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunotherapy comes of age. Nature (2011) 12.35
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62
Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother (2012) 1.05